These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 29316940)

  • 1. Gamma-delta (γδ) T cells: friend or foe in cancer development?
    Zhao Y; Niu C; Cui J
    J Transl Med; 2018 Jan; 16(1):3. PubMed ID: 29316940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy.
    Liu Y; Zhang C
    Cells; 2020 May; 9(5):. PubMed ID: 32413966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.
    Rei M; Pennington DJ; Silva-Santos B
    Cancer Res; 2015 Mar; 75(5):798-802. PubMed ID: 25660949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.
    Li Y; Li G; Zhang J; Wu X; Chen X
    Front Immunol; 2020; 11():619954. PubMed ID: 33664732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
    Miyashita M; Shimizu T; Ashihara E; Ukimura O
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
    Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
    Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Function of γδ T cells in tumor immunology and their application to cancer therapy.
    Park JH; Lee HK
    Exp Mol Med; 2021 Mar; 53(3):318-327. PubMed ID: 33707742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human γδT-cell subsets and their involvement in tumor immunity.
    Wu D; Wu P; Qiu F; Wei Q; Huang J
    Cell Mol Immunol; 2017 Mar; 14(3):245-253. PubMed ID: 27890919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
    Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
    Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer immunotherapy with γδ T cells: many paths ahead of us.
    Kabelitz D; Serrano R; Kouakanou L; Peters C; Kalyan S
    Cell Mol Immunol; 2020 Sep; 17(9):925-939. PubMed ID: 32699351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting gamma delta T cells for cancer immunotherapy: bench to bedside.
    Gogoi D; Chiplunkar SV
    Indian J Med Res; 2013 Nov; 138(5):755-61. PubMed ID: 24434328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. γδ T Cells in Tumor Microenvironment.
    Imbert C; Olive D
    Adv Exp Med Biol; 2020; 1273():91-104. PubMed ID: 33119877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. γδ cells and tumor microenvironment: A helpful or a dangerous liason?
    Lo Presti E; Di Mitri R; Pizzolato G; Mocciaro F; Dieli F; Meraviglia S
    J Leukoc Biol; 2018 Mar; 103(3):485-492. PubMed ID: 29345336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?
    Galati D; Zanotta S; Bocchino M; De Filippi R; Pinto A
    Cancer Immunol Immunother; 2021 Jul; 70(7):1797-1809. PubMed ID: 33386466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
    Gomes AQ; Martins DS; Silva-Santos B
    Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing γδ T cells in anticancer immunotherapy.
    Hannani D; Ma Y; Yamazaki T; Déchanet-Merville J; Kroemer G; Zitvogel L
    Trends Immunol; 2012 May; 33(5):199-206. PubMed ID: 22364810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. γδ T cells and the PD-1/PD-L1 axis: a love-hate relationship in the tumor microenvironment.
    Liu J; Wu M; Yang Y; Wang Z; He S; Tian X; Wang H
    J Transl Med; 2024 Jun; 22(1):553. PubMed ID: 38858763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
    Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
    Front Immunol; 2018; 9():1990. PubMed ID: 30298063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer.
    Paul S; Lal G
    Int J Cancer; 2016 Sep; 139(5):976-85. PubMed ID: 27012367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.